Literature DB >> 17918965

Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate.

Guanglei Cui1, Kenneth M Merz.   

Abstract

Studies aimed at elucidating the reaction mechanism of farnesyltransferase (FTase), which catalyzes the prenylation of many cellular signaling proteins including Ras, has been an active area of research. Much is known regarding substrate binding and the impact of various catalytic site residues on catalysis. However, the molecular level details regarding the conformational rearrangement of farnesyldiphosphate (FPP), which has been proposed via structural analysis and mutagenesis studies to occur prior to the chemical step, is still poorly understood. Following on our previous computational characterization of the resting state of the FTase ternary complex, the thermodynamics of the conformational rearrangement step in the absence of magnesium was investigated for the wild type FTase and the Y300Fbeta mutant complexed with the peptide CVIM. In addition, we also explored the target dependence of the conformational activation step by perturbing isoleucine into a leucine (CVLM). The calculated free energy profiles of the proposed conformational transition confirm the presence of a stable intermediate state, which was identified only when the diphosphate is monoprotonated (FPP2-). The farnesyl group in the computed intermediate state assumes a conformation similar to that of the product complex, particularly for the first two isoprene units. We found that Y300beta can readily form hydrogen bonds with either of the phosphates of FPP. Removing the hydroxyl group on Y300beta does not significantly alter the thermodynamics of the conformational transition, but shifts the location of the intermediate farther away from the nucleophile by 0.5 A, which suggests that Y300beta facilitate the reaction by stabilizing the chemical step. Our results also showed an increased transition barrier height for CVLM (1.5 kcal/mol higher than that of CVIM). Although qualitatively consistent with the findings from the recent kinetic isotope experiments by Fierke and co-workers, the magnitude is not large enough to affect the rate-limiting step.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918965      PMCID: PMC2570014          DOI: 10.1021/bi701324t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  27 in total

Review 1.  Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

Authors:  Ronald J Doll; Paul Kirschmeier; W Robert Bishop
Journal:  Curr Opin Drug Discov Devel       Date:  2004-07

2.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

Authors:  T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  J Mol Biol       Date:  2004-10-15       Impact factor: 5.469

Review 3.  Membrane association and targeting of prenylated Ras-like GTPases.

Authors:  M C Seabra
Journal:  Cell Signal       Date:  1998-03       Impact factor: 4.315

Review 4.  Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins.

Authors:  M D Resh
Journal:  Cell Signal       Date:  1996-09       Impact factor: 4.315

5.  Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution.

Authors:  H W Park; S R Boduluri; J F Moomaw; P J Casey; L S Beese
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

Review 6.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

7.  Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation.

Authors:  Jennifer S Pickett; Katherine E Bowers; Heather L Hartman; Hua-Wen Fu; Alan C Embry; Patrick J Casey; Carol A Fierke
Journal:  Biochemistry       Date:  2003-08-19       Impact factor: 3.162

8.  Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

Authors:  S Rao; D Cunningham; A de Gramont; W Scheithauer; M Smakal; Y Humblet; G Kourteva; T Iveson; T Andre; J Dostalova; A Illes; R Belly; J J Perez-Ruixo; Y C Park; P A Palmer
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

Review 9.  Farnesyl transferase inhibitors in clinical development.

Authors:  Francesco Caponigro; Marina Casale; Jane Bryce
Journal:  Expert Opin Investig Drugs       Date:  2003-06       Impact factor: 6.206

10.  Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.

Authors:  Fadlo R Khuri; Bonnie S Glisson; Edward S Kim; Paul Statkevich; Peter F Thall; Michael L Meyers; Roy S Herbst; Reginald F Munden; Craig Tendler; Yali Zhu; Sandra Bangert; Elizabeth Thompson; Charles Lu; Xue-Mei Wang; Dong M Shin; Merrill S Kies; Vali Papadimitrakopoulou; Frank V Fossella; Paul Kirschmeier; W Robert Bishop; Waun Ki Hong
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

View more
  9 in total

1.  Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase.

Authors:  Yue Yang; Dhruva K Chakravorty; Kenneth M Merz
Journal:  Biochemistry       Date:  2010-11-09       Impact factor: 3.162

2.  Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.

Authors:  Carl Högberg; Olof Gidlöf; Francesca Deflorian; Kenneth A Jacobson; Aliaa Abdelrahman; Christa E Müller; Björn Olde; David Erlinge
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

3.  Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity.

Authors:  Thangaiah Subramanian; Suxia Liu; Jerry M Troutman; Douglas A Andres; H Peter Spielmann
Journal:  Chembiochem       Date:  2008-11-24       Impact factor: 3.164

4.  Molecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif.

Authors:  Sérgio F Sousa; João T S Coimbra; Diogo Paramos; Rita Pinto; Rodrigo S Guimarães; Vitor Teixeira; Pedro A Fernandes; Maria J Ramos
Journal:  J Mol Model       Date:  2012-09-26       Impact factor: 1.810

5.  Catalytic mechanism of aromatic prenylation by NphB.

Authors:  Yue Yang; Yipu Miao; Bing Wang; Guanglei Cui; Kenneth M Merz
Journal:  Biochemistry       Date:  2012-03-12       Impact factor: 3.162

6.  Insights into the mechanistic dichotomy of the protein farnesyltransferase peptide substrates CVIM and CVLS.

Authors:  Yue Yang; Bing Wang; Melek N Ucisik; Guanglei Cui; Carol A Fierke; Kenneth M Merz
Journal:  J Am Chem Soc       Date:  2012-01-06       Impact factor: 15.419

7.  Farnesyl diphosphate analogues with aryl moieties are efficient alternate substrates for protein farnesyltransferase.

Authors:  Thangaiah Subramanian; June E Pais; Suxia Liu; Jerry M Troutman; Yuta Suzuki; Karunai Leela Subramanian; Carol A Fierke; Douglas A Andres; H Peter Spielmann
Journal:  Biochemistry       Date:  2012-10-02       Impact factor: 3.162

8.  Simultaneous Site-Specific Dual Protein Labeling Using Protein Prenyltransferases.

Authors:  Yi Zhang; Melanie J Blanden; Ch Sudheer; Soumyashree A Gangopadhyay; Mohammad Rashidian; James L Hougland; Mark D Distefano
Journal:  Bioconjug Chem       Date:  2015-12-04       Impact factor: 4.774

Review 9.  Role of substrate dynamics in protein prenylation reactions.

Authors:  Dhruva K Chakravorty; Kenneth M Merz
Journal:  Acc Chem Res       Date:  2014-12-24       Impact factor: 22.384

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.